AstraZeneca acquires Modella AI to accelerate oncology drug development with foundation models

AstraZeneca Acquisition Marks First AI Purchase by Major Pharma

AstraZeneca has acquired Modella AI, a Boston-based startup specializing in artificial intelligence models for biomedical research, marking what the company describes as the first acquisition of an AI firm by a major pharmaceutical company 1

1

. The financial terms of the deal were not disclosed, but the move signals a decisive shift in how the pharmaceutical industry approaches oncology drug development 2

2

. Announced at the JP Morgan Healthcare Conference, the AstraZeneca acquisition extends a multi-year collaboration that began in July, which AstraZeneca Chief Financial Officer Aradhana Sarin described as a "test drive" before bringing Modella AI's data, foundation models, and talent in-house 1

1

.

Foundation Models and AI Agents Transform Oncology Research

Modella AI designs foundation models and AI agents capable of analyzing complex clinical data and identifying relevant biomarkers for oncology research 2

2

. These tools will be integrated into AstraZeneca's global clinical trials to support R&D and biomarker discovery efforts 1

1

. Gabi Raia, Modella AI's chief commercial officer, emphasized that "oncology drug development is becoming more complex, more data-rich and more time-sensitive," adding that joining AstraZeneca would enable deployment of its tools in global trials and clinical settings 1

1

. The acquisition aims to "supercharge" AstraZeneca's quantitative pathology capabilities by using computers to analyze biopsies for relevant proteins and correlate them with clinical data, according to Aradhana Sarin 1

1

.

Patient Selection for Drug Trials and Development Costs

The integration of artificial intelligence models is expected to refine biopsy analysis, improve patient selection for drug trials, and reduce development costs across AstraZeneca's oncology pipeline 2

2

. Sarin noted that AI tools could be used to more rapidly select patients for clinical trials, which could increase the odds of clinical success and cut related costs 1

1

. By making pathology more quantitative, AstraZeneca aims to develop "highly targeted biomarkers and then highly targeted therapeutics" 1

1

. This approach addresses the growing complexity of the development of new cancer treatments, where precise target identification and efficient patient matching can significantly impact trial outcomes and timelines.

AI Adoption in Pharmaceutical Sector Accelerates

The deal represents part of a broader wave of AI adoption in pharmaceutical sector partnerships unveiled at the healthcare conference. A notable example includes a $1 billion collaboration between Nvidia and Eli Lilly to build a new research lab using Nvidia's latest-generation AI chips 1

1

2

2

. These developments suggest that major pharmaceutical companies are moving beyond exploratory partnerships toward full integration of AI capabilities, bringing data and technological tools in-house to maintain competitive advantage in drug discovery and clinical development. For AstraZeneca, the acquisition strengthens internal capabilities in quantitative pathology and therapeutic target identification, positioning the company to leverage AI across its oncology portfolio while potentially setting a precedent for how the pharmaceutical industry structures future AI investments.